Yi-Nan Zhang

Staff Scientist at @scrippsresearch @lab_zhu working on vaccine development | PhD @bme_uoft @TheChanLab

[Yi-Nan Zhang @YN_Zhang]

Our HA‑based influenza protein nanoparticle paper has been published. Congrats to the team. @lab_zhu @scrippsresearch

[Scripps Research @scrippsresearch]

A new @NatureComms study from Jiang Zhu's lab reports a structure-guided strategy to stabilize influenza hemagglutinin (HA) trimers for nanoparticle vaccines. In preclinical models, the nanoparticles showed prolonged lymph node retention and elicited more robust immune responses.

More: https://t.co/Ax0kIHi3us

[Scripps Research @scrippsresearch]

Stabilizing the hepatitis C virus E1E2 glycoprotein complex—long a barrier to HCV vaccine design—Scripps Research scientists displayed engineered proteins on self-assembling nanoparticles, eliciting immune responses in a new @NatureComms study. More: https://t.co/eswPGJb2L1

[Scripps Research @scrippsresearch]

A structure-guided nanoparticle designed by @lab_zhu and published in @NatureComms (currently an Article-in-Press) stabilizes Ebola and Marburg surface proteins in their pre-fusion shape—prompting a strong antibody response in preclinical models and laying the foundation for a universal filovirus vaccine. More: https://t.co/Or5I8tgDSp

[Yi-Nan Zhang @YN_Zhang]

Our filovirus nanoparticle vaccine paper "Rational design of next-generation filovirus vaccines combining glycoprotein stabilization and nanoparticle display with glycan modification" has been published. Congrats to the team @lab_zhu @scrippsresearch.
https://t.co/3rp7lIG6PB

[Yi-Nan Zhang @YN_Zhang]

Our HA-based influenza protein nanoparticle paper has now appeared on bioRxiv. Congrats to the team @lab_zhu @scrippsresearch😀

[bioRxiv Microbiology @biorxiv_micrbio]

Single-component self-assembling protein nanoparticles displaying stabilized prefusion-closed hemagglutinin trimers for influenza ... https://t.co/SHRMzc4Bta #biorxiv_micrbio

[Scripps Research @scrippsresearch]

Former Scripps Research assistant professor Shimon Sakaguchi has been awarded the 2025 #NobelPrize in Physiology or Medicine for his discovery of regulatory T cells that drive peripheral immune tolerance, a mechanism of the immune system that prevents autoimmune disease and reveals how cancer escapes immune attack.

His work launched a new field of research on peripheral immune tolerance, paving the way for therapies now in clinical trials for cancer, autoimmune disease and transplant complications.

A former assistant professor at Scripps Research (1989–1991), Sakaguchi leaves a lasting impact on biomedical science and the institute’s legacy. Congratulations to Professor Sakaguchi and all of this year’s Nobel laureates.

More: https://t.co/fGsDBKTtU6

[Yi-Nan Zhang @YN_Zhang]

A milestone moment: our HIV-1 protein nanoparticle vaccine candidates move to the human trial in US, adjuvanted with 3M-052-AF + Alum, sponsored by NIH/NIAID😀 @lab_zhu
https://t.co/0dWcFI62VK

[Yiming Jason Zhang @Y_Jason_Zhang]

We found that antigen deposition on follicular dendritic cells is the key in driving strong germinal center response. | Science Translational Medicine https://t.co/OsbUyhJHmO

[Yi-Nan Zhang @YN_Zhang]

Our HCV nanoparticle vaccine paper "Native-like soluble E1E2 glycoprotein heterodimers on self-assembling protein nanoparticles for hepatitis C virus vaccine design" was published on bioRxiv. @lab_zhu @scrippsresearch😀

[bioRxiv Microbiology @biorxiv_micrbio]

Native-like soluble E1E2 glycoprotein heterodimers on self-assembling protein nanoparticles for hepatitis C virus vaccine design https://t.co/ZtCgp4KoDR #biorxiv_micrbio

[The Chan Lab @TheChanLab]

🚨New Paper 🚨

Bram et al. identified how nanoparticle charge interfaces with the cellular glycocalyx, dramatically affecting nanoparticle delivery. This enabled a new approach to improve nanoparticle targeting!

🔗 https://t.co/y3T3JNpSJA

[CEPI @CEPIvaccines]

📣Efforts to advance the first-ever vaccine against the deadly Middle East Respiratory Syndrome are progressing, with a new CEPI investment moving a promising vaccine candidate created by Uvax Bio into preclinical trials.

https://t.co/LCJeFH2QQ1

[The Chan Lab @TheChanLab]

🚨🚨NEW PAPER ALERT🚨🚨

@jamielywu et al. discovered the pathways tumour endothelial cells use to transport nanoparticles.

Link to paper: https://t.co/omGzAiJUzx

Below is a thread by Dr. Jamie Wu summarising the method and results:

[The Chan Lab @TheChanLab]

🚨New Paper🚨

@MladScientist et al. utilized 3D electron microscopy to visualize and study the transport of nanoparticles across tumour blood vessels.

Link to paper: https://t.co/rRYfsoNNmF

Below is a thread summarising the method and results:

[Yi-Nan Zhang @YN_Zhang]

Our filovirus vaccine paper "Rational design of next-generation filovirus vaccines with glycoprotein stabilization, nanoparticle display, and glycan modification" appears on bioRxiv. Congrats to Zhu lab team @lab_zhu, @scrippsresearch 😀

[bioRxiv Microbiology @biorxiv_micrbio]

Rational design of next-generation filovirus vaccines with glycoprotein stabilization, nanoparticle display, and glycan modification https://t.co/goVtqNlVPw #biorxiv_micrbio

[Scripps Research @scrippsresearch]

In a new op-ed for @sdut, Scripps Research President & CEO Pete Schultz explains how changes to federal science funding could impact biomedical research, innovation & San Diego’s life sciences ecosystem. https://t.co/qOXAdP4uam

[Yi-Nan Zhang @YN_Zhang]

A tale of two fusion proteins: RSV-F and hMPV-F https://t.co/kstvEDp6KM

[Scripps Research @scrippsresearch]

Unstable F proteins have hindered RSV and hMPV vaccines, but after analyzing their structure, the @lab_zhu uncovered instability caused by an “acidic patch” and re-engineered RSV F proteins to enhance stability and efficacy in pre-clinical models. More: https://t.co/IU7Okj40Jy

[Yi-Nan Zhang @YN_Zhang]

Researchers use biophysics to design new vaccines against RSV and related respiratory viruses | Scripps Research
https://t.co/IbsXCP8ZLp

[Yi-Nan Zhang @YN_Zhang]

Our RSV and hMPV vaccines' paper "Rational design of uncleaved prefusion-closed trimer vaccines for human respiratory syncytial virus and metapneumovirus" was published. 😀Congrats to Zhu lab team
@lab_zhu, @scrippsresearch.
https://t.co/geGDHKVgec

[The Nobel Prize @NobelPrize]

BREAKING NEWS
The Royal Swedish Academy of Sciences has decided to award the 2024 #NobelPrize in Chemistry with one half to David Baker “for computational protein design” and the other half jointly to Demis Hassabis and John M. Jumper “for protein structure prediction.”